Skip to Content

Infanrix Penta

Active Substance: diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis-B surface antigen / poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain))
Common Name: diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (adsorbed)
ATC Code: J07CA12
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis-B surface antigen / poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain))
Status: Withdrawn
Authorisation Date: 2000-10-23
Therapeutic Area: Hepatitis B Diphtheria Poliomyelitis Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Infanrix Penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B and poliomyelitis.

This marketing authorisation for Infanrix Penta has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide